Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 vaccine-induced high-titer convalescent plasma
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
SARS-CoV-2 vaccine-induced high-titer convalescent plasma is a blood-derived biologic product obtained from donors who have undergone a sequential vaccination strategy against COVID-19. This plasma is characterized by high titers of neutralizing antibodies specifically targeting the SARS-CoV-2 virus. Unlike traditional convalescent plasma, which is sourced from individuals who have recovered from a natural infection, this product utilizes the standardized and often more robust immune response elicited by vaccination. It is intended for use in patients requiring blood transfusions to provide passive protection against COVID-19 infection and to evaluate the safety and immunologic effects of such transfusions. The product is currently being studied in a Phase 0 clinical trial by Jiangsu Provincial People's Hospital.
- Other names
- SARS-CoV-2 vaccine-induced high-titer plasmaSARS-CoV2 vaccine-induced high-titer plasmaSARS-CoV 2 vaccine-induced high-titer plasmaPlasma from COVID-19 sequential-vaccinated donors
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 vaccine-induced high-titer convalescent plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 vaccine-induced high-titer convalescent plasma.